|
1
|
Baue AE, Durham R and Faist E: Systemic
inflammatory response syndrome (SIRS), multiple organ dysfunction
syndrome (MODS), multiple organ failure (MOF): are we winning the
battle? Shock. 10:79–89. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murata A, Kikuchi M, Mishima S, et al:
Cytokine imbalance in critically ill patients: SIRS and CARS. Nihon
Geka Gakkai Zasshi. 100:414–418. 1999.(In Japanese).
|
|
3
|
Mayer J, Rau B, Gansauge F and Beger HG:
Inflammatory mediators in human acute pancreatitis: clinical and
pathophysiological implications. Gut. 47:546–552. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Brady M, Christmas S, Sutton R,
Neoptolemos J and Slavin J: Cytokines and acute pancreatitis.
Baillieres Best Pract Res Clin Gastroenterol. 13:265–289. 1999.
View Article : Google Scholar
|
|
5
|
Hirota M, Nozawa F, Okabe A, et al:
Relationship between plasma cytokine concentration and multiple
organ failure in patients with acute pancreatitis. Pancreas.
21:141–146. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Goris RJ: MODS/SIRS: result of an
overwhelming inflammatory response? World J Surg. 20:418–421. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Beaux AC, Goldie AS, Ross JA, Carter DC
and Fearon KC: Serum concentrations of inflammatory mediators
related to organ failure in patients with acute pancreatitis. Br J
Surg. 83:349–353. 1996.PubMed/NCBI
|
|
8
|
Brivet FG, Emilie D and Galanaud P: Pro-
and anti-inflammatory cytokines during acute severe pancreatitis:
an early and sustained response, although unpredictable of death.
Parisian Study Group on Acute Pancreatitis. Crit Care Med.
27:749–755. 1999. View Article : Google Scholar
|
|
9
|
Bamias G and Cominelli F:
Immunopathogenesis of inflammatory bowel disease: current concepts.
Curr Opin Gastroenterol. 23:365–369. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brennan F and Beech J: Update on cytokines
in rheumatoid arthritis. Curr Opin Rheumatol. 19:296–301. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kyttaris VC, Juang YT and Tsokos GC:
Immune cells and cytokines in systemic lupus erythematosus: an
update. Curr Opin Rheumatol. 17:518–522. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suarez A, Lopez P, Mozo L and Gutierrez C:
Differential effect of IL10 and TNFα genotypes on determining
susceptibility to discoid and systemic lupus erythematosus. Ann
Rheum Dis. 64:1605–1610. 2005.
|
|
13
|
Hanauer SB: Inflammatory bowel disease:
epidemiology, pathogenesis, and therapeutic opportunities. Inflamm
Bowel Dis. 12(Suppl 1): S3–S9. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Podolsky DK: Inflammatory bowel disease. N
Engl J Med. 347:417–429. 2002.
|
|
15
|
Scott DL: Early rheumatoid arthritis. Br
Med Bull. 81–82:97–114. 2007.
|
|
16
|
Meesters EW, Hansen H, Spronk HM, et al:
The inflammation and coagulation cross-talk in patients with
systemic lupus erythematosus. Blood Coagul Fibrinolysis. 18:21–28.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim HR, Cho ML, Kim KW, et al:
Up-regulation of IL-23p19 expression in rheumatoid arthritis
synovial fibroblasts by IL-17 through PI3-kinase-, NF-kappaB- and
p38 MAPK-dependent signalling pathways. Rheumatology (Oxford).
46:57–64. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu FL, Chen CH, Chu SJ, et al:
Interleukin (IL)-23 p19 expression induced by IL-1beta in human
fibroblast-like synoviocytes with rheumatoid arthritis via active
nuclear factor-kappaB and AP-1 dependent pathway. Rheumatology
(Oxford). 46:1266–1273. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Metsios GS, Stavropoulos-Kalinoglou A,
Douglas KM, et al: Blockade of tumour necrosis factor-alpha in
rheumatoid arthritis: effects on components of rheumatoid cachexia.
Rheumatology (Oxford). 46:1824–1827. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nixon R, Bansback N and Brennan A: The
efficacy of inhibiting tumour necrosis factor alpha and interleukin
1 in patients with rheumatoid arthritis: a meta-analysis and
adjusted indirect comparisons. Rheumatology (Oxford). 46:1140–1147.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
van der Kooij SM, Allaart CF, Dijkmans BA
and Breedveld FC: Innovative treatment strategies for patients with
rheumatoid arthritis. Curr Opin Rheumatol. 20:287–294.
2008.PubMed/NCBI
|
|
22
|
Wiesendanger M, Stanevsky A, Kovsky S and
Diamond B: Novel therapeutics for systemic lupus erythematosus.
Curr Opin Rheumatol. 18:227–235. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Faioni EM, Ferrero S, Fontana G, et al:
Expression of endothelial protein C receptor and thrombomodulin in
the intestinal tissue of patients with inflammatory bowel disease.
Crit Care Med. 32(Suppl 5): S266–S270. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nojima J, Kuratsune H, Suehisa E, et al:
Acquired activated protein C resistance is associated with the
co-existence of anti-prothrombin antibodies and lupus anticoagulant
activity in patients with systemic lupus erythematosus. Br J
Haematol. 118:577–583. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Johnson RM, Barone RM, Newson BL, Das
Gupta TK and Nyhus LM: Treatment of experimental acute pancreatitis
with 5-flourouracil (5-FU). Am J Surg. 125:211–222. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Saario IA: 5-Fluorouracil in the treatment
of acute pancreatitis. Am J Surg. 145:349–352. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Muller CA, Vogeser M, Belyaev O, et al:
Role of endogenous glucocorticoid metabolism in human acute
pancreatitis. Crit Care Med. 34:1060–1066. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rakonczay Z Jr, Duda E, Kaszaki J, et al:
The anti-inflammatory effect of methylprednisolone occurs
down-stream of nuclear factor-kappaB DNA binding in acute
pancreatitis. Eur J Pharmacol. 464:217–227. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Luo S, Wang R, Jiang W, Lin X, Qiu P and
Yan G: A novel recombinant snake venom metalloproteinase from
Agkistrodon acutus protects against taurocholate-induced
severe acute pancreatitis in rats. Biochimie. 92:1354–1361. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lederer JA and Czuprynski CJ: Production
and purification of bovine monocyte-derived interleukin 1. Vet
Immunol Immunopathol. 23:201–211. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kimura H, Ishibashi T, Shikama Y, Okano A,
Akiyama Y, Uchida T and Maruyama Y: Interleukin-1 beta (IL-1 beta)
induces thrombocytosis in mice: possible implication of IL-6.
Blood. 76:2493–2500. 1990.PubMed/NCBI
|
|
32
|
Heo DS, Park JG, Hata K, Day R, Herberman
RB and Whiteside TL: Evaluation of tetrazolium-based semiautomatic
colorimetric assay for measurement of human antitumor cytotoxicity.
Cancer Res. 50:3681–3690
|
|
33
|
Hirota M, Nozawa F, Okabe A, Shibata M,
Kuwata K and Ogawa M: SIRS and CARS: discussion based on the
pathologic condition of acute pancreatitis. Jpn J Clin Pathol.
48:527–532. 2000.(In Japanese).
|
|
34
|
Ono S, Ichikura T and Mochizuki H: The
pathogenesis of the systemic inflammatory response syndrome and
compensatory antiinflammatory response syndrome following surgical
stress. Nihon Geka Gakkai Zasshi. 104:499–505. 2003.(In
Japanese).
|
|
35
|
Ammori BJ, Leeder PC, King RF, et al:
Early increase in intestinal permeability in patients with severe
acute pancreatitis: correlation with endotoxemia, organ failure,
and mortality. J Gastrointest Surg. 3:252–262. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Schmid SW, Uhl W, Friess H, Malfertheiner
P and Buchler MW: The role of infection in acute pancreatitis. Gut.
45:311–316. 1999. View Article : Google Scholar
|
|
37
|
Pitchumoni CS, Patel NM and Shah P:
Factors influencing mortality in acute pancreatitis: can we alter
them? J Clin Gastroenterol. 39:798–814. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bumbasirevic V, Radenkovic D, Jankovic Z,
et al: Severe acute pancreatitis: overall and early versus late
mortality in intensive care units. Pancreas. 38:122–125. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ziegler EJ, Fisher CJ Jr, Sprung CL, et
al: Treatment of gram-negative bacteremia and septic shock with
HA-1A human monoclonal antibody against endotoxin. A randomized,
double-blind, placebo-controlled trial. The HA-1A Sepsis Study
Group. N Engl J Med. 324:429–436. 1991. View Article : Google Scholar
|
|
40
|
Stack AM, Saladino RA, Siber GR, et al: A
comparison of bactericidal/permeability-increasing protein variant
versus recombinant endotoxin-neutralizing protein for the treatment
of Escherichia coli sepsis in rats. Crit Care Med.
25:101–105. 1997. View Article : Google Scholar
|
|
41
|
Jiang J, Zhu P, Wang Z, et al: Protective
effect of bactericidal/permeability-increasing protein in mice with
E. coli sepsis. Chin J Traumatol. 1:21–24. 1998.PubMed/NCBI
|
|
42
|
Fisher CJ Jr, Agosti JM, Opal SM, et al:
Treatment of septic shock with the tumor necrosis factor receptor:
Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N
Engl J Med. 334:1697–1702. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Clark MA, Plank LD, Connolly AB, et al:
Effect of a chimeric antibody to tumor necrosis factor-alpha on
cytokine and physiologic responses in patients with severe sepsis -
a randomized, clinical trial. Crit Care Med. 26:1650–1659. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Reinhart K, Wiegand-Lohnert C, Grimminger
F, et al: Assessment of the safety and efficacy of the monoclonal
anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients
with sepsis and septic shock: a multicenter, randomized,
placebo-controlled, dose-ranging study. Crit Care Med. 24:733–742.
1996. View Article : Google Scholar
|
|
45
|
Fisher CJ Jr, Slotman GJ, Opal SM, et al:
Initial evaluation of human recombinant interleukin-1 receptor
antagonist in the treatment of sepsis syndrome: a randomized,
open-label, placebo-controlled multicenter trial. Crit Care Med.
22:12–21. 1994.
|
|
46
|
Fink G, Yang J, Carter G and Norman J:
Acute pancreatitis-induced enzyme release and necrosis are
attenuated by IL-1 antagonism through an indirect mechanism. J Surg
Res. 67:94–97. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Opal SM, Fisher CJ Jr, Dhainaut JF, et al:
Confirmatory interleukin-1 receptor antagonist trial in severe
sepsis: a phase III, randomized, double-blind, placebo-controlled,
multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis
Investigator Group. Crit Care Med. 25:1115–1124. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Dhainaut JF, Tenaillon A, Hemmer M, et al:
Confirmatory platelet-activating factor receptor antagonist trial
in patients with severe gram-negative bacterial sepsis: a phase
III, randomized, double-blind, placebo-controlled, multicenter
trial. BN 52021 Sepsis Investigator Group. Crit Care Med.
26:1963–1971. 1998. View Article : Google Scholar
|
|
49
|
Zimmerman GA, McIntyre TM, Prescott SM and
Stafforini DM: The platelet-activating factor signaling system and
its regulators in syndromes of inflammation and thrombosis. Crit
Care Med. 30(Suppl 5): S294–S301. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Poeze M, Froon AH, Ramsay G, Buurman WA
and Greve JW: Decreased organ failure in patients with severe SIRS
and septic shock treated with the platelet-activating factor
antagonist TCV-309: a prospective, multicenter, double-blind,
randomized phase II trial. TCV-309 Septic Shock Study Group. Shock.
14:421–428. 2000. View Article : Google Scholar
|
|
51
|
Osman MO, Kristensen JU, Jacobsen NO, et
al: A monoclonal anti-interleukin 8 antibody (WS-4) inhibits
cytokine response and acute lung injury in experimental severe
acute necrotising pancreatitis in rabbits. Gut. 43:232–239. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Rhee P, Morris J, Durham R, et al:
Recombinant humanized monoclonal antibody against CD18 (rhuMAb
CD18) in traumatic hemorrhagic shock: results of a phase II
clinical trial. Traumatic Shock Group. J Trauma. 49:611–620. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Allison DE, Gourlay SG, Koren E, Miller RM
and Fox JA: Pharmacokinetics of rhuMAb CD18, a recombinant
humanised monoclonal antibody fragment to CD18, in normal healthy
human volunteers. BioDrugs. 16:63–70. 2002. View Article : Google Scholar
|
|
54
|
Iwagaki H, Hizuta A, Uomoto M, et al:
Clinical value of cytokine antagonists in infectious complications.
Res Commun Mol Pathol Pharmacol. 96:25–34. 1997.PubMed/NCBI
|
|
55
|
Remick DG: Cytokine therapeutics for the
treatment of sepsis: why has nothing worked? Curr Pharm Des.
9:75–82. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yan SB, Helterbrand JD, Hartman DL, Wright
TJ and Bernard GR: Low levels of protein C are associated with poor
outcome in severe sepsis. Chest. 120:915–922. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bernard GR, Vincent JL, Laterre PF, et al:
Efficacy and safety of recombinant human activated protein C for
severe sepsis. N Engl J Med. 344:699–709. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Jansen PM, Eisele B, de Jong IW, et al:
Effect of C1 inhibitor on inflammatory and physiologic response
patterns in primates suffering from lethal septic shock. J Immunol.
160:475–484. 1998.PubMed/NCBI
|
|
59
|
Caliezi C, Zeerleder S, Redondo M, et al:
C1-inhibitor in patients with severe sepsis and septic shock:
beneficial effect on renal dysfunction. Crit Care Med.
30:1722–1728. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Oberholzer A, Oberholzer C, Efron PA, et
al: Functional modification of dendritic cells with recombinant
adenovirus encoding interleukin 10 for the treatment of sepsis.
Shock. 23:507–515. 2005.PubMed/NCBI
|
|
61
|
Rajan S, Vyas D, Clark AT, et al:
Intestine-specific overexpression of IL-10 improves survival in
polymicrobial sepsis. Shock. 29:483–489. 2008.PubMed/NCBI
|
|
62
|
Wijngaarden S, van Roon JA, van de Winkel
JG, Bijlsma JW and Lafeber FP: Down-regulation of activating
Fcgamma receptors on monocytes of patients with rheumatoid
arthritis upon methotrexate treatment. Rheumatology (Oxford).
44:729–734. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Soon SY, Ansari A, Yaneza M, Raoof S,
Hirst J and Sanderson JD: Experience with the use of low-dose
methotrexate for inflammatory bowel disease. Eur J Gastroenterol
Hepatol. 16:921–926. 2004. View Article : Google Scholar : PubMed/NCBI
|
